Trials / Conditions / Arthritis, Juvenile Rheumatoid

Arthritis, Juvenile Rheumatoid

17 registered clinical trials studyying Arthritis, Juvenile Rheumatoid — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis NCT06000566	Yesfa Sebnem Ozbay	—
Completed	Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing NCT02067962	University Hospital, Montpellier	N/A
Enrolling By Invitation	Juvenile Inflammatory Rheumatism (JIR) Cohorte NCT02377245	Michaël Hofer	—
Completed	Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis NCT01412021	AbbVie	—
Terminated	Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis NCT00637780	Pfizer	Phase 4
Completed	A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects NCT00807846	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4
Completed	Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA NCT02001844	University of Newcastle, Australia	N/A
Terminated	Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis NCT00688545	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	—
Terminated	Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis NCT00868751	Tufts Medical Center	N/A
Completed	Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis NCT00731965	N.M. Wulffraat	Phase 4
Terminated	Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease NCT00511329	Nationwide Children's Hospital	Phase 2 / Phase 3
Completed	Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Art NCT00426218	Novartis	Phase 1 / Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patient NCT00652925	Pfizer	Phase 3
Completed	Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) NCT00034853	Boehringer Ingelheim	Phase 3
Completed	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile NCT00279747	Boehringer Ingelheim	Phase 3
Completed	The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis NCT00001614	National Eye Institute (NEI)	Phase 1
Unknown	The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile NCT00012506	National Eye Institute (NEI)	Phase 3